TRENTON, N.J., March 7, 2023 /PRNewswire/ — BioNJ is pleased to host its 13th Annual BioPartnering Conference on Tuesday, April 18, 2023, at The Palace at Somerset Park, Somerset, NJ. Back in person after three years, the Conference will bring together life sciences executives, investors, academic collaborators and business development professionals for networking, 1-1 partnering (including in-person on the day of the Conference and virtual partnering throughout the rest of the week), company and start-up pitches, exhibits and plenary sessions.
“We’re thrilled to partner once again with J.P. Morgan and Johnson & Johnson Innovation on BioNJ’s BioPartnering Conference, and are ecstatic to have Morgan Lewis join this elite group of Conference Partners for 2023. These organizations are dedicated to strengthening the ecosystem and supporting the life sciences industry in bringing new therapies and medicines to Patients,” said Debbie Hart, President and CEO, BioNJ.
“With a robust full-day agenda ─ including a highly anticipated networking reception offering the perfect opportunity to connect with future partners and investors ─ this year’s Conference is on track to be bigger than ever,” added Hart. “Last year’s program convened over 500 attendees from 18 states as well as the District of Columbia, 11 countries and more than 100 investors looking for new opportunities in which to invest.”
The action-packed schedule is designed to foster productive partnerships, create meaningful opportunities, grow the ecosystem and bolster medical innovation. Attendees will hear from and interact with industry thought leaders, such as…
- Kathleen Addison, Executive Director, Life Sciences, J.P. Morgan
- Amit Bhalla, M.P.H., MBA, CFO, Sampled
- Steve Brugger, Former CEO, Affinivax (Acquired by GSK)
- Samuele Butera, President, US Pulmonary Hypertension and Retina, President, US Pulmonary Hypertension and Retina, The Janssen Pharmaceutical Companies of Johnson & Johnson
- Dana Callow, MBA, Managing Partner, Boston Millennia Partners
- Kathleen Coviello, Chief Economic Transformation Officer, New Jersey Economic Development Authority
- Mahako Etta, Program Manager, New Jersey Commission on Science, Innovation and Technology
- Chris Gartin, Managing Director, Healthcare Investment Banking, J.P. Morgan
- Sal Giovine, CFO, Pharmaceutical BD & External Innovation, Johnson & Johnson
- Debbie Hart, President & CEO, BioNJ
- Paul Howard, Ph.D., Senior Director, Public Policy, Amicus Therapeutics
- Nitin Khanna, CEO, Archer Insights
- Alan Leeds, Partner, Morgan Lewis
- Rik Mehta, CEO, Lactiga
- Mike Poisel, MS, MBA, Executive Director, Penn Center for Innovation
- Ravi Raghunathan, Partner, Life Sciences Leader, CohnReznick
- John Ritter, JD, MBA, Director, Office of Technology Licensing, Princeton University
- Phil Ross, Global Chair, Investment Banking, J.P. Morgan
- David Schwartz, Partner, Morgan Lewis
- Gina Tedesco, Managing Director, Golden Seeds
- Ofra Weinberger, Ph.D., Director of Licensing, Columbia Tech Ventures; Associate VP, Tech Transfer & Intellectual Property, Columbia University, Columbia Tech Ventures
- Michael Wiley, JD, MBA, Vice President, Foundation Venture Capital Group
- Marshall Woodworth, CFO, Nevakar
Timely plenary sessions include:
- Biotech Industry Overview: Stats, Trends & Lay of the Land
- Partnering & Raising Capital — Best Practices in the Recovering Biotech Sector
- Navigating the Journey from Start-Up to Commercialization
- Fireside Chat with Dana Callow, Managing Partner, Boston Millennia Partners
- The Path to Successful Value Creation and Partnering with Higher Education Institutions and Academic Medical Centers
- A Whole New Day at the NJEDA and Beyond: Raising Capital via Government-Supported Programs
Plus, a special session will showcase the winners from BioNJ’s Inaugural Health Equity in Clinical Trials MBA Case Competition. On December 3, 2022, eight teams, competing for more than $20,000 in prize money, presented a business plan defining a new solution, application or technology that can be used nationally to strengthen diversity in clinical trials and expand health equity. During this session, attendees will hear from the three winning teams as they present their business plans live. Click here to peruse the resumes of the students from all eight teams.
The program will include a record number of Company and Start-Up Pitches from innovative companies across life science, biotech, healthcare and digital health sectors…presenting companies to be announced in the next two weeks!
Attendees will also have the opportunity to meet and hear from representatives from world-renowned institutions as they discuss the importance of academic-industry collaboration in driving medical innovation forward.
- Columbia Technology Ventures at Columbia University
- New Jersey Institute of Technology
- New York University
- Princeton University
- Rowan University
- Rutgers University
- University of Pennsylvania
- The Wistar Institute
In addition, attendees can visit the Industry Showcase to learn about valuable resources, products and services available to companies in our BioNJ community:
- Amicus Therapeutics
- Centri
- Cohn Reznick
- DLA Piper
- Johnson & Johnson Innovation
- J.P. Morgan
- Marcum
- Merck & Co.
- Middlesex County
- Morgan Lewis
- New Jersey Economic Development Authority
- New Jersey Health Foundation
- RSM
- SciSafe
- Withum
- Worldwide IP Solutions
- Thermo Fisher Scientific
Make sure you don’t miss this unique opportunity to meet new partners, identify new opportunities and learn new ideas. Click here to register. Registration is $395 for BioNJ Members and $495 for Future Members. Contact Pavita Howe at [email protected] with questions and Cheri Hennessy at [email protected] to learn about Sponsorship and Exhibit opportunities.
Media Contact
Randi Bromberg
Sr. Vice President, Communications and Marketing
O) 609-890-3185
C) 609-955-1067
[email protected]
SOURCE BioNJ
